ストックスクリーナーアプリを入手
13.08
3.15%
0.40
プレマーケット:
13.08
前日終値:
$12.68
開ける：
$12.78
24時間の取引高:
1.45M
Relative Volume:
0.72
時価総額：
$1.53B
収益：
$59.61M
当期純損益:
$-262.14M
株価収益率:
-3.3367
EPS:
-3.92
ネットキャッシュフロー:
$-247.49M
1週間 パフォーマンス:
-1.51%
1か月 パフォーマンス:
-12.74%
6か月 パフォーマンス:
+34.15%
1年 パフォーマンス:
+302.46%
1日の値動き範囲:
$12.78
$13.37
1週間の範囲:
$12.61
$14.36
52週間の値動き範囲:
$3.295
$16.20
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
名前
Arcutis Biotherapeutics Inc
セクター
電話
805-418-5006
住所
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
ARQT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
13.08 | 1.53B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-08-28 | 開始されました | Jefferies | Buy |
| 2024-01-03 | アップグレード | Mizuho | Neutral → Buy |
| 2023-10-26 | ダウングレード | Mizuho | Buy → Neutral |
| 2023-10-13 | ダウングレード | Goldman | Buy → Neutral |
| 2022-09-07 | 開始されました | Needham | Buy |
| 2022-03-17 | 開始されました | Goldman | Buy |
| 2021-06-30 | 開始されました | Mizuho | Buy |
| 2021-05-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | アップグレード | Goldman | Neutral → Buy |
| 2020-10-08 | 開始されました | Truist | Buy |
| 2020-02-25 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-02-25 | 開始されました | Cowen | Outperform |
| 2020-02-25 | 開始されました | Goldman | Neutral |
| 2020-02-25 | 開始されました | Guggenheim | Buy |
すべてを表示
Arcutis Biotherapeutics Inc (ARQT) 最新ニュース
Objective long/short (ARQT) Report - Stock Traders Daily
Short Interest in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Decreases By 9.3% - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 4%Time to Sell? - MarketBeat
Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 37.43%: Here's is How to Trade - Yahoo Finance
Arcutis Biotherapeutics’ (ARQT) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Arcutis stock target lifted, buy rating held on significant developments By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap UpStill a Buy? - MarketBeat
Arcutis stock target lifted, buy rating held on significant developments - Investing.com India
Arcutis Biotherapeutics' (ARQT) Buy Rating Reiterated at HC Wainwright - MarketBeat
Demystifying Arcutis Biotherapeutics: Insights From 5 Analyst Reviews - Benzinga
JPMorgan Chase & Co. Raises Stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World
Arcutis Shares Climb on Strong Product Revenue Estimates - MarketWatch
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket - Benzinga
Arcutis Biotherapeutics, Inc. Announces Preliminary Unaudited Earnings Guidance for Fourth Quarter and Full Year 2024 - Marketscreener.com
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million - The Manila Times
Arcutis Q4 Revenue Surges 366% to $63M as ZORYVE Demand Accelerates Across Indications - StockTitan
Rajvir Madan Joins Arcutis as Chief Digital and Information Officer -June 01, 2021 at 07:30 am EDT - Marketscreener.com
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 8.5%Here's What Happened - MarketBeat
Commit To Purchase Arcutis Biotherapeutics At $7.50, Earn 21.3% Using Options - Nasdaq
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Expected to Rise, Mizuho Analyst Says - Defense World
When the Price of (ARQT) Talks, People Listen - Stock Traders Daily
Mizuho Forecasts Strong Price Appreciation for Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Sets New 52-Week HighHere's What Happened - MarketBeat
Arcutis stock soars to 52-week high, hits $15.85 amid robust gains - Investing.com
Mizuho lifts Arcutis stock price target to $20, maintains Outperform By Investing.com - Investing.com Australia
Arcutis Biotherapeutics director Welgus sells $146,714 in stock By Investing.com - Investing.com Nigeria
Mizuho lifts Arcutis stock price target to $20, maintains Outperform - Investing.com
Insider Selling: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Director Sells 10,000 Shares of Stock - MarketBeat
Arcutis Biotherapeutics director Welgus sells $146,714 in stock - Investing.com
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Biotherapeutics Grants 75,500 RSUs to New Hires in Strategic Talent Acquisition Move - StockTitan
Here's Why Arcutis Stock More Than Doubled In Market Value In One Year - Barchart
Here's Why Arcutis Stock More Than Doubled in Market Value in One Year - MSN
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading 7% HigherHere's Why - MarketBeat
Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment? - Simply Wall St
What is HC Wainwright’s Forecast for ARQT FY2024 Earnings? - Defense World
FY2024 Earnings Estimate for ARQT Issued By HC Wainwright - MarketBeat
Arcutis Biotherapeutics CMO Patrick Burnett sells shares for $23,674 By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Patrick Burnett Sells 1,691 Shares - MarketBeat
Arcutis Biotherapeutics CMO Patrick Burnett sells shares for $23,674 - Investing.com India
Looking Ahead to 2025 Dermatology Drug Approvals - Dermatology Times
H.C. Wainwright initiates Buy on Arcutis Biotherapeutics shares highlighting Zoryve potential - Investing.com Canada
HC Wainwright & Co. Initiates Coverage of Arcutis Biotherapeutics (ARQT) with Buy Recommendation - MSN
Arcutis Biotherapeutics Inc (ARQT) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):